癌症中的更多 T 细胞受体？
More T cell receptors to the RAScue in cancer?
出版信息
J Clin Invest. 2024 Nov 1;134(21):e184782. doi: 10.1172/JCI184782.
Abstract
Treatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four HLA-A03:01- or HLA-A11:01-restricted TCRs targeting the oncogenic KRAS G12V mutation. The TCRs were derived from healthy donors or patients with pancreatic cancer who had received a vaccine against mutant KRAS. The most promising TCRs warrant testing in patients with KRAS G12V-positive cancers.
摘要
用基因工程改造表达肿瘤反应性 T 细胞受体（TCRs）的 T 细胞进行治疗，称为 TCR 基因治疗（TCR-T），是癌症患者有前途的免疫治疗方法。鉴定最佳 TCRs 和肿瘤抗原靶点是 TCR-T 的关键考虑因素。在本期 JCI 中，Bear 及其同事报告了他们使用体外检测方法来鉴定四种 HLA-A03:01 或 HLA-A11:01 限制的 TCR，这些 TCR 靶向致癌性 KRAS G12V 突变。这些 TCR 来自接受针对突变 KRAS 疫苗的健康供体或胰腺癌患者。最有前途的 TCR 需要在 KRAS G12V 阳性癌症患者中进行测试。
相似文献
1
More T cell receptors to the RAScue in cancer?癌症中的更多 T 细胞受体？
J Clin Invest. 2024 Nov 1;134(21):e184782. doi: 10.1172/JCI184782.
2
Targeting KRAS mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.针对实体瘤中 HLA Ⅱ类限制 TCR 靶向 KRAS 突变的免疫治疗。
Front Immunol. 2023 May 23;14:1161538. doi: 10.3389/fimmu.2023.1161538. eCollection 2023.
3
Identification and affinity enhancement of T-cell receptor targeting a KRAS cancer neoantigen.鉴定和增强针对 KRAS 癌症新抗原的 T 细胞受体的亲和力。
Commun Biol. 2024 Apr 29;7(1):512. doi: 10.1038/s42003-024-06209-2.
4
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.天然 TCR 靶向 KRASG12V 对人类实体肿瘤具有良好的特异性和敏感性。
J Clin Invest. 2024 Sep 17;134(21):e175790. doi: 10.1172/JCI175790.
5
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.高亲和力寡克隆 TCR 定义了针对突变 KRAS-G12D 的有效过继性 T 细胞治疗。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835. doi: 10.1073/pnas.1921964117. Epub 2020 May 27.
6
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.靶向KRAS突变型人类肿瘤的T细胞受体的鉴定
Cancer Immunol Res. 2016 Mar;4(3):204-14. doi: 10.1158/2326-6066.CIR-15-0188. Epub 2015 Dec 23.
7
In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.体外蛋白酶体对新剪接表位的加工并不预测其在体内的呈现。
Elife. 2021 Apr 20;10:e62019. doi: 10.7554/eLife.62019.
8
[Preclinical study of T cell receptor specifically reactive with G12V mutation in the treatment of malignant tumors].[T细胞受体对G12V突变特异性反应在恶性肿瘤治疗中的临床前研究]
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):884-895. doi: 10.19723/j.issn.1671-167X.2022.05.016.
9
Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.鉴定针对 MAGE-A3 和 MAGE-A12 的 HLA-A*01 限制性和 C*07 限制性表位的 T 细胞受体。
J Immunother. 2012 Nov-Dec;35(9):680-8. doi: 10.1097/CJI.0b013e31827338ea.
10
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.利用 HLA Ⅱ类限制性 TCR 靶向 KRAS 突变治疗实体瘤。
Oncoimmunology. 2021 Jun 17;10(1):1936757. doi: 10.1080/2162402X.2021.1936757. eCollection 2021.
本文引用的文献
1
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.天然 TCR 靶向 KRASG12V 对人类实体肿瘤具有良好的特异性和敏感性。
J Clin Invest. 2024 Sep 17;134(21):e175790. doi: 10.1172/JCI175790.
2
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.过继转移个性化新抗原反应性 TCR 转导 T 细胞治疗转移性结直肠癌：2 期试验中期结果。
Nat Med. 2024 Sep;30(9):2586-2595. doi: 10.1038/s41591-024-03109-0. Epub 2024 Jul 11.
3
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.肿瘤浸润淋巴细胞治疗或伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233.
4
Non-viral precision T cell receptor replacement for personalized cell therapy.非病毒精准 T 细胞受体替换用于个性化细胞治疗。
Nature. 2023 Mar;615(7953):687-696. doi: 10.1038/s41586-022-05531-1. Epub 2022 Nov 10.
5
Neoantigen-Specific T Cells in Adoptive Cell Therapy.过继细胞疗法中的新抗原特异性 T 细胞。
Cancer J. 2022;28(4):278-284. doi: 10.1097/PPO.0000000000000605.
6
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.采用自体肿瘤浸润淋巴细胞和靶向人实体瘤常见 p53 新抗原的 T 细胞受体工程化 T 细胞的过继细胞疗法。
Cancer Immunol Res. 2022 Aug 3;10(8):932-946. doi: 10.1158/2326-6066.CIR-22-0040.
7
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.用于胰腺癌的新抗原 T 细胞受体基因治疗。
N Engl J Med. 2022 Jun 2;386(22):2112-2119. doi: 10.1056/NEJMoa2119662.
8
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.针对致癌 KRAS 突变的 T 细胞靶点的系统发现和验证。
Cell Rep Methods. 2021 Sep 16;1(5):100084. doi: 10.1016/j.crmeth.2021.100084. eCollection 2021 Sep 27.
9
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.突变 KRAS 表位的生化和功能特征使该癌蛋白成为免疫靶向治疗的有效靶点。
Nat Commun. 2021 Jul 16;12(1):4365. doi: 10.1038/s41467-021-24562-2.
10
Identification and Validation of T-cell Receptors Targeting Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.鉴定和验证针对人类癌症热点突变的 T 细胞受体，用于基于细胞的免疫治疗。
Clin Cancer Res. 2021 Sep 15;27(18):5084-5095. doi: 10.1158/1078-0432.CCR-21-0849. Epub 2021 Jun 24.
Zotero 插件